A nested cohort 5-year Canadian surveillance of Gram-negative antimicrobial resistance for optimized antimicrobial therapy

• Published in: Scientific reports 2023-08, Vol.13 (1), p.14142-14142, Article 14142
• Main Authors: Blondeau, Joseph, Charles, Marthe Kenny, Loo, Vivian, Adam, Heather, Gonzalez Del Vecchio, Marcela, Ghakis, Christiane, O’Callaghan, Emma, El Ali, Radwan
• Format: Article
• Language: English
• Subjects: 631/326; 692/420; 692/699; 692/700; Antimicrobial agents; Antimicrobial resistance; Ceftazidime; Colistin; Drug resistance; E coli; Humanities and Social Sciences; Infections; Meropenem; multidisciplinary; Multidrug resistance; Pathogens; Piperacillin; Respiratory tract; Respiratory tract infection; Science; Science (multidisciplinary); Surveillance; Tazobactam; Urinary tract
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-40012-z

We analyzed 5 years (2016–2020) of nested Canadian data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) to identify pathogen predominance and antimicrobial resistance (AMR) patterns of adult Gram-negative infections in Canadian health care and to complement other public surveillance programs and studies in Canada. A total of 6853 isolates were analyzed from medical (44%), surgical (18%), intensive care (22%) and emergency units (15%) and from respiratory tract (36%), intra-abdominal (25%), urinary tract (24%) and bloodstream (15%) infections. Overall, E. coli (36%), P. aeruginosa (18%) and K. pneumoniae (12%) were the most frequent isolates and P. aeruginosa was the most common respiratory pathogen. 18% of Enterobacterales species were ESBL positive. Collective susceptibility profiles showed that P. aeruginosa isolates were highly susceptible (> 95%) to ceftolozane/tazobactam and colistin, though markedly less susceptible (58–74%) to other antimicrobials tested. Multi-drug resistance (MDR) was present in 10% of P. aeruginosa isolates and was more frequent in those from respiratory infections and from ICU than non-ICU locations. Of P. aeruginosa isolates that were resistant to combinations of ceftazidime, piperacillin/tazobactam and meropenem, 73–96% were susceptible to ceftolozane/tazobactam over the period of the study. These national data can now be combined with clinical prediction rules and genomic data to enable expert antimicrobial stewardship applications and guide treatment policies to optimize adult patient care.